These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 18551040)

  • 1. Naturalistic pharmacogenetic study of treatment resistance to typical neuroleptics in European-Brazilian schizophrenics.
    Kohlrausch FB; Gama CS; Lobato MI; Belmonte-de-Abreu P; Callegari-Jacques SM; Gesteira A; Barros F; Carracedo A; Hutz MH
    Pharmacogenet Genomics; 2008 Jul; 18(7):599-609. PubMed ID: 18551040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness.
    de Leon J; Susce MT; Pan RM; Koch WH; Wedlund PJ
    J Clin Psychopharmacol; 2005 Oct; 25(5):448-56. PubMed ID: 16160620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The polymorphisms of candidate pharmacokinetic and pharmacodynamic genes and their pharmacogenetic impacts on the effectiveness of risperidone maintenance therapy among Saudi children with autism.
    Shilbayeh SAR; Adeen IS; Alhazmi AS; Aljurayb H; Altokhais RS; Alhowaish N; Aldilaijan KE; Kamal M; Alnakhli AM
    Eur J Clin Pharmacol; 2024 Jun; 80(6):869-890. PubMed ID: 38421437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The combined effect of CYP2D6 and DRD2 Taq1A polymorphisms on the antipsychotics daily doses and hospital stay duration in schizophrenia inpatients (observational naturalistic study).
    Kurylev AA; Brodyansky VM; Andreev BV; Kibitov AO; Limankin OV; Mosolov SN
    Psychiatr Danub; 2018 Jun; 30(2):157-163. PubMed ID: 29930225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacogenetic assessment of antipsychotic-induced tardive dyskinesia: contribution of 5-hydroxytryptamine 2C receptor gene and of a combination of dopamine D3 variant allele (Gly) and MnSOD wild allele (Val)].
    Zhang Z; Hou G; Zhang X; Yao H; Sha W; Zhang X
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2003 Apr; 20(2):98-102. PubMed ID: 12673575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of CYP2D6, CYP3A5, and ABCB1 gene polymorphisms on the pharmacokinetics of two risperidone long-acting injection microsphere formulations.
    Ma L; Xiang Q; Zhao N; Hu C; Fang M; Tan Y; Chen S; Wang Z; Liu P; Sun K; Li Y; Wu F; Tian H; Fang M; Zhao X; Wang G; Cui Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jul; 109():110241. PubMed ID: 33400943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of DRD2 and DRD3 polymorphisms with Parkinson's disease in a multiethnic consortium.
    McGuire V; Van Den Eeden SK; Tanner CM; Kamel F; Umbach DM; Marder K; Mayeux R; Ritz B; Ross GW; Petrovitch H; Topol B; Popat RA; Costello S; Manthripragada AD; Southwick A; Myers RM; Nelson LM
    J Neurol Sci; 2011 Aug; 307(1-2):22-9. PubMed ID: 21663922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetics in American Indian populations: analysis of CYP2D6, CYP3A4, CYP3A5, and CYP2C9 in the Confederated Salish and Kootenai Tribes.
    Fohner A; Muzquiz LI; Austin MA; Gaedigk A; Gordon A; Thornton T; Rieder MJ; Pershouse MA; Putnam EA; Howlett K; Beatty P; Thummel KE; Woodahl EL
    Pharmacogenet Genomics; 2013 Aug; 23(8):403-14. PubMed ID: 23778323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ABCB1, ABCG2 and CYP2D6 polymorphism effects on disposition and response to long-acting risperidone.
    Ganoci L; Trkulja V; Živković M; Božina T; Šagud M; Lovrić M; Božina N
    Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jan; 104():110042. PubMed ID: 32682874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment.
    Fiegenbaum M; da Silveira FR; Van der Sand CR; Van der Sand LC; Ferreira ME; Pires RC; Hutz MH
    Clin Pharmacol Ther; 2005 Nov; 78(5):551-8. PubMed ID: 16321621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic polymorphisms in the dopamine-2 receptor (DRD2), dopamine-3 receptor (DRD3), and dopamine transporter (SLC6A3) genes in schizophrenia: Data from an association study.
    Sáiz PA; García-Portilla MP; Arango C; Morales B; Arias B; Corcoran P; Fernández JM; Alvarez V; Coto E; Bascarán MT; Bousoño M; Fañanas L; Bobes J
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Feb; 34(1):26-31. PubMed ID: 19766158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association Between the Lower Extremity Deep Venous Thrombosis, the Warfarin Maintenance Dose, and CYP2C9*3, CYP2D6*10, and CYP3A5*3 Genetic Polymorphisms: A Case-Control Study.
    Ju S; Gao Y; Cao X; Zhang XF; Yan CC; Liu FT
    Genet Test Mol Biomarkers; 2017 Sep; 21(9):539-546. PubMed ID: 28872889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations.
    Hwang R; Shinkai T; De Luca V; Müller DJ; Ni X; Macciardi F; Potkin S; Lieberman JA; Meltzer HY; Kennedy JL
    Psychopharmacology (Berl); 2005 Aug; 181(1):179-87. PubMed ID: 15830237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting.
    Alenius M; Wadelius M; Dahl ML; Hartvig P; Lindström L; Hammarlund-Udenaes M
    J Psychiatr Res; 2008 Sep; 42(11):884-93. PubMed ID: 18086475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The dopamine D3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia: a haplotype relative risk study and association with clozapine response.
    Malhotra AK; Goldman D; Buchanan RW; Rooney W; Clifton A; Kosmidis MH; Breier A; Pickar D
    Mol Psychiatry; 1998 Jan; 3(1):72-5. PubMed ID: 9491816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia.
    Basile VS; Masellis M; Badri F; Paterson AD; Meltzer HY; Lieberman JA; Potkin SG; Macciardi F; Kennedy JL
    Neuropsychopharmacology; 1999 Jul; 21(1):17-27. PubMed ID: 10379516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytochrome P450 genotypes are not associated with refractoriness to antipsychotic treatment.
    van de Bilt MT; Prado CM; Ojopi EP; Sousa RT; Loch AA; Zanetti MV; Talib LL; Gattaz WF
    Schizophr Res; 2015 Oct; 168(1-2):587-8. PubMed ID: 26298540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo.
    He P; Court MH; Greenblatt DJ; Von Moltke LL
    Clin Pharmacol Ther; 2005 May; 77(5):373-87. PubMed ID: 15900284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic polymorphisms in dopaminergic system and treatment-resistant schizophrenia.
    Terzić T; Kastelic M; Dolžan V; Plesničar BK
    Psychiatr Danub; 2016 Jun; 28(2):127-31. PubMed ID: 27287786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. European Multicentre Association Study of Schizophrenia: a study of the DRD2 Ser311Cys and DRD3 Ser9Gly polymorphisms.
    Spurlock G; Williams J; McGuffin P; Aschauer HN; Lenzinger E; Fuchs K; Sieghart WC; Meszaros K; Fathi N; Laurent C; Mallet J; Macciardi F; Pedrini S; Gill M; Hawi Z; Gibson S; Jazin EE; Yang HT; Adolfsson R; Pato CN; Dourado AM; Owen MJ
    Am J Med Genet; 1998 Feb; 81(1):24-8. PubMed ID: 9514583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.